Alpha Tau & Healthcare Capital Corp. to Combine and Create A $1-Billion Publicly Traded Company

Alpha Tau Medical (Israel) & Healthcare Capital Corp. (US) to Combine and Create A $1-Billion Publicly Traded Company Focused on Transforming the Treatment of Solid Tumors Through the Precision Delivery of Alpha Radiation


HekaBio’s partner Alpha Tau Medical Ltd has announced on July 9 (July 8, local time) that it will form a public company with Healthcare Capital Corp (Nasdaq: HCCC), a special purpose acquisition company, to be listed on the Nasdaq stock exchange by the end of 2021.


Click here for the original press release.



About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau Medical Ltd, is an Israeli oncology therapeutics company that focuses on research, development, and commercialization of the Alpha DaRT™ technology for the treatment of solid tumors.

Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors. The treatment is delivered by intratumoral insertion of radionuclide Radium-224, which leads to the release and diffusion of daughter radioisotopes that emit alpha particles. These alpha particles have the capacity to destroy solid tumors. Since the alpha-emitting atoms diffuse only a short distance in tissue, Alpha DaRT mainly damages the tumor, while sparing the healthy tissue around it.



最新記事

すべて表示

HekaBio Completes Financing Round

HekaBio K.K. announced today that it has successfully completed a financing round of JPY 400 million. Proceeds will be used to strengthen and expand HekaBio’s portfolio of innovations in development i